Dr. Lior Shaltiel reports

NUREXONE ANNOUNCES VOTING RESULTS FROM 2024 ANNUAL MEETING OF SHAREHOLDERS

Nurexone Biologic Inc. has released the voting results from its annual general and special meeting of shareholders held on Monday, June 3, 2024, by live webcast. Shareholders voted overwhelmingly in favour of each resolution put forth at the meeting at a passing rate of over 99 per cent.

At the meeting, there were 41 shareholders represented in person or by proxy holding 20,329,922 common shares in the capital of the Company ("Common Shares"), representing 30.88% of the Company's issued and outstanding Common Shares as at the record date for the Meeting, which was 65,830,428 Common Shares.

Each nominee listed in the Company's management information circular dated April 19, 2024, was elected as a director of the Company. Each director will serve until the next annual meeting of Shareholders or until his or her successor is duly elected or appointed. The results of which were as follows:

In addition, at the Meeting, Shareholders: (i) reappointed Ziv Haft, CPA (Isr.), a BDO member firm, as the Company's auditor for the ensuing year and authorized the board of directors to fix their compensation; (ii) approved an amendment to the Company's omnibus equity incentive plan (the "Equity Incentive Plan") to increase the number of Common Shares reserved for issuance to participants to 13,166,085, which represented 20% of the issued and outstanding Common Shares as of the record date; and (iii) authorized a continuance of the Company from the Province of Alberta to the Province of Ontario (the "Continuance"). The results of such votes were as follows:

We thank all of our Shareholders who participated at the Meeting.

Equity Incentive Plan Grants

The Company is also pleased to announce the grant of stock options (each, an "Option") and restricted share units (each, an "RSU") pursuant to the Equity Incentive Plan. The Company granted an aggregate of 1,815,900 Options and an aggregate of 2,000,000 RSUs to certain certain officers, directors, employees, and consultants of the Company. Each Option is exercisable to purchase one Common Share at a price of $0.51 per Common Share for a period of ten years; 580,000 Options vest in equal quarterly installments over a one-year period and the remaining 1,235,900 Options vest over a two-year period with 50% vesting on the one-year anniversary and the remaining 50% vesting in equal quarterly installments over the second year.

Each RSU granted vests on the one-year anniversary and upon such vesting will be settled into a Common Share.

Certain Options and RSUs (and any Common Shares issuable upon their exercise and settlement) are subject to the Exchange Hold Period pursuant and as defined in the policies of the TSX Venture Exchange ("TSXV").

About Nurexone Biologic Inc.

Nurexone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The Nurexone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

We seek Safe Harbor.